logo-loader
viewElixir Energy Ltd

Elixir Petroleum identifies new petroleum play type in France

au_europe__350_519eadbfdc748.jpg

Elixir Petroleum (ASX: EXR) has identified a new petroleum play type targeting conventional reservoirs in large Carboniferous thrust anticlines at its Moselle Permit in the Saar Lorraine Basin, France.

While Stephanian play was not the target of past wells, there are five historic wells that intersect parts of the Stephanian sequence in the Moselle Permit.

Analysis of core and well logs demonstrates reservoir quality, while reprocessed seismic, which has been corrected for static issues, has identified large anticline structures.

Substantial potential is also present in the more traditionally exploited existing play types in the Lower Triassic, which host the nearby La Trois Fontaine gas field and the Forcelles oil field, and Westphalian, where gas to surface has been achieved in a number of historic wells.

Work carried out by Elixir has focused on three prospects:

-    Nancy East, targeting stacked Stephanian anticlinal closures;
-    Bullseye, stacked lower Triassic and Stephanian hangingwall closures; and
-    West Chaumont, broad faulted anticline with Triassic closure.

With the aim of verifying the extensive internal technical work undertaken by Elixir, RPS Energy Services has been engaged to provide an Independent Resources Report in relation to these conventional prospects in Moselle.

The final report is expected within the next few weeks.

Elixir remains actively engaged with interested parties regarding a potential farm-out based on conventional prospectivity.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Elixir Energy Ltd

Price: 0.031 AUD

ASX:EXR
Market: ASX
Market Cap: $15.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

31 minutes ago

2 min read